on NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides' NV-387 Receives Orphan Drug Designation for Measles Treatment
NanoViricides, Inc., based in Shelton, CT, announced that its antiviral drug NV-387 has been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of measles. This designation offers benefits, including tax credits for clinical trials, exemption from certain fees, and seven years of market exclusivity post-approval.
Dr. Anil R. Diwan from NanoViricides emphasized that this milestone will expedite NV-387's development, crucial amidst the global resurgence of measles, notably in regions like Bangladesh and Guatemala. Rising measles cases in the US bolster the need for such treatments.
NV-387 shows potent in vivo activity against the measles virus, marking it as a unique candidate in the struggle against this highly contagious disease. The company also seeks a Rare Pediatric Disease Drug designation for NV-387, which could provide further regulatory advantages.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NanoViricides, Inc. news